CRF Announces Press Conference Schedule for TCT 2015

Newswise — NEW YORK, NY – September 22, 2015 – The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 in San Francisco, California.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Monday, October 12; Tuesday, October 13; Wednesday, October 14; and Thursday, October 15.

The complete agenda for TCT 2015 is also available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty on the TCT Web site.

Media are invited to attend TCT. If you are unable to attend in person, you may still cover it remotely via Virtual TCT. Registering as media ensures that you have access to all of the press conferences, trial data, abstracts, and press releases. More information on press credentials and guidelines can be found at http://www.crf.org/tct/press/press-credentials-and-guidelines. To apply for press credentials, visit: http://www.crf.org/tct/press/press-registration-form.

TCT 2015 Press Conference ScheduleMonday, October 12, 20159:15 AM – 10:30 AM

Moderator: Roxana Mehran, MDDiscussants: Marie-Claude Morice, MD; Daniel I. Simon, MD; Pascal Vranckx, MD, PhD

9:15 AM A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and InterventionShigeru Saito, MD

9:30 AM ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease Run-Lin Gao, MD

9:45 AMABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease Dean J. Kereiakes, MD

10:00 AMABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease – Two-Year OutcomesBernard R. Chevalier, MD

10:15 AMBIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold – Six-Month Clinical, Angiographic, and Imaging Outcomes Michael Haude, MDTuesday, October 13, 20159:00 AM – 10:15 AM

Moderator: Ori Ben-Yehuda, MDDiscussants: Bernard De Bruyne, MD, PhD; Nico H.J. Pijls, MD, PhD; Marco Valgimigli, MD, PhD

9:00 AMRIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention Giora Weisz, MD

9:15 AM EXPLORE: A Prospective Randomized Trial of Chronic Total Occlusion Intervention Versus Medical Therapy After Successful Primary Angioplasty in Patients With ST-Segment Elevation Myocardial InfarctionJose P.S. Henriques, MD

9:30 AMTOTAL: A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction – One-Year Outcomes Sanjit S. Jolly, MD, MSc

9:45 AM A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD

10:00 AM PLATFORM: Quality-of-Life and Economic Outcomes of an FFR-CT Diagnostic Strategy in Patients With Suspected Coronary Artery Disease Mark Andrew Hlatky, MD

Wednesday, October 14, 20159:00 AM – 10:15 AM

Moderator: George D. Dangas, MD, PhDDiscussants: TBD

9:00 AMLEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding Philip M. Urban, MD

9:15 AMTUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease Upendra Kaul, MD

9:30 AMPANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics Xu Bo, MD

9:45 AMISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis Robert A. Byrne, MB, BCh, PhD

10:00 AMIN.PACT SFA: A Prospective Randomized Trial of a Drug-Coated Balloon for Femoropopliteal Lesions – Two-Year OutcomesJohn R. Laird Jr, MD

Thursday, October 15, 20159:00 AM – 10:15 AM

Moderator: Ajay J. Kirtane, MD, SMDiscussants: Samir R. Kapadia, MD; Roxana Mehran, MD; Jeffrey J. Popma, MD

9:00 AMBRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve Replacement Thierry Lefevre, MD

9:15 AMSAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis – One-Year Outcomes Howard C. Herrmann, MD

9:30 AMRESPECT: A Prospective Randomized Trial of PFO Closure In Patients With Cryptogenic Stroke - Long-Term Results John D. Carroll, MD

9:45 AMEvaluation of Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic Stenosis Tomohiko Taniguchi, MD

10:00 AMPARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves Danny Dvir, MD

Receive updates on Twitter: https://twitter.com/TCTConference.

About CRF and TCTThe Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit www.crf.org and www.tctconference.com.